Showing 1851-1860 of 2123 results for "".
- Duvyzat Approved by FDA As Treatment for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/duvyzat-approved-by-fda-as-treatment-for-duchenne-muscular-dystrophy/2470429/Duvyzat (givinostat; Italfarmaco SpA, Milan, Italy), a histone deacetylase (HDAC) inhibitor, was approved by the Food and Drug Administration (FDA) to treat Duchenne muscular dystrophy (DMD) in individuals aged >6 years. This is the first nonsteroidal drug approved to treat DMD. FDA
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- Endovascular Thrombectomy Improves Functional Outcomes Long Term in Patients with Large Vessel Occlusion Ischemic Strokehttps://practicalneurology.com/news/endovascular-thrombectomy-improves-functional-outcomes-long-term-in-patients-with-large-vessel-occlusion-ischemic-stroke/2470401/Endovascular thrombectomy (EVT) improved functional outcomes in patients with anterior circulation large vessel occlusion ischemic stroke and large ischemic core at 1 year of follow up, according to long-term results from the SELECT2 clinical trial (NCT03876457). EVT also met secondary outcomes a
- Anticoagulation Therapy Does Not Reduce Risk of Recurrent Stroke Compared with Aspirin in Those with Cryptogenic Stroke and Atrial Cardiopathyhttps://practicalneurology.com/news/anticoagulation-therapy-does-not-reduce-risk-of-recurrent-stroke-compared-with-aspirin-in-those-with-cryptogenic-stroke-and-atrial-cardiopathy/2470399/Treatment with Eliquis (apixaban; Bristol Myers Squibb, New York, NY), an anticoagulant medication, did not significantly reduce the risk of recurrent stroke compared with aspirin therapy in people with cryptogenic stroke and evidence of atrial cardiopathy. The findings of the ARCADIA clinical tr
- Boston Scientific’s Spinal Cord Stimulation Systems Effective at Reducing Back Painhttps://practicalneurology.com/news/boston-scientifics-spinal-cord-stimulation-systems-effective-at-reducing-back-pain/2470387/Using the WaveWriter and WaveWriter Alpha Spinal Cord Stimulation (SCS) Systems (Boston Scientific, Marlborough, MA) resulted in sustained pain relief as treatment for non-surgical back pain (NSBP), according to positive 1-year results from the SOLIS clinical trial (NCT04676022). These findi
- Promising Results from Study of Stem Cell Transplantation in People with Multiple Sclerosis Publishedhttps://practicalneurology.com/news/promising-results-from-study-of-stem-cell-transplantation-in-people-with-multiple-sclerosis-published/2470351/One-year results from a phase I clinical trial (NCT03282760) demonstrated the feasibility, safety, and tolerability of intracerebroventricular (ICV) human neural stem/progenitor cell (hNSC) transplantation in patients with secondary progressive multiple sclerosis (SPMS). Results were published in
- Breakthrough Device Designation Granted to Roche’s Elecsys Neurofilament Light Chain Test for Multiple Sclerosishttps://practicalneurology.com/news/breakthrough-device-designation-granted-to-roches-elecsys-neurofilament-light-chain-test-for-multiple-sclerosis/2470350/Roche’s Elecsys neurofilament light chain (NfL) test (Basel, Switzerland) received breakthrough device designation from the Food and Drug Administration (FDA). The test is intended to be used to detect disease activity in the serum and plasma of adults aged 18 to 55 years with relapsing-rem
- Recipients of the “Frontiers in Headache Research Scholarship Award” from the American Headache Society Announcedhttps://practicalneurology.com/news/recipients-of-the-frontiers-in-headache-research-scholarship-award-from-the-american-headache-society-announced/2470341/Ten recipients of the American Headache Society (AHS) Frontiers in Headache Research Scholarship Award have received complimentary meeting registration for the 2023 Scottsdale Headache Symposium, a travel stipend of up to $1000, and a full year of AHS Trainee membership. The AHS awards this schol
- FDA Grants Fast Track Designation to Investigational RNA Replacement Enzyme-Based Cancer Gene Therapy to Treat Glioblastomahttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-investigational-rna-replacement-enzyme-based-cancer-gene-therapy-to-treat-glioblastoma/2470336/RZ-001 (Rznomics; Yongin-si, South Korea), a candidate RNA replacement enzyme-based cancer gene therapy, has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for patients with glioblastoma (GBM). RZ-001 is designed to target